Abstract:Abstract A 3-year-old boy with type IV skin presented in May 2021 with a 5-month history of a pigmented line in his right fourth fingernail. Examination revealed a 1-mm uniform darkly pigmented band (1.2 mm at proximal aspect) of triangular longitudinal melanonychia with positive pseudo-Hutchinson and negative Hutchinson sign. A clinical diagnosis of benign subungual naevus was made. The patient had a background of neurofibromatosis type 1 and ganglioglioma of the brainstem and right cerebellar peduncle treated with chemotherapy. First- and second-line regimens – vincristine plus carboplatin in 2019–2020, and TPCV (thioguanine, procarbazine, lomustine and vincristine) in 2020 to April 2021 – had been trialled unsuccessfully before dermatology review. In October 2021, the patient commenced trametinib 0.5 mg once daily for his progressive ganglioglioma. Within 4 months, the longitudinal melanonychia had involuted significantly. Dermoscopy demonstrated faded melanonychia with a small residual blueish linear pigmentation remaining proximally (reduced to 0.8 mm). Pseudo-Hutchinson sign was now negative. The patient’s trametinib was discontinued for around 10 days in July 2022 due to mucositis and sepsis and his melanonychia subsequently darkened and extended further distally over the following 3 months. In November 2022 his trametinib dose was decreased to 0.37 mg due to ongoing mucositis and infection. However, the dark band was not as pronounced as at the initial presentation. He remained on the reduced trametinib dose, and by January 2024 the melanonychia had faded and appeared as a 1-mm uniform pale-brown longitudinal streak. He also developed multiple new naevi on his face, trunk, buttocks and genital area during this period. Trametinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has been used in targeted therapies against various malignancies, including in combination with BRAF inhibitors against metastatic melanoma. A lesser-reported complication of targeted therapies includes ‘lightening’ of pigmented naevi. Hypopigmentation, or involution or regression has been reported in patients receiving single-agent BRAF inhibitor or combined BRAF–MEK therapy. However, ours is the first reported case of a single-agent MEK inhibitor causing regression of a subungual naevus as a side-effect. The mechanism behind naevus involution in patients receiving targeted therapy is unclear, with proposed models focusing on the impact of BRAF rather than MEK inhibition. This case highlights a stark temporal relationship between trametinib therapy and the involution and subsequent redevelopment of a benign longitudinal melanonychia. This adds to our growing understanding of the impact of targeted therapies on melanocytic naevi, which patients and doctors should be aware of.

A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma

A Preclinical Model of Patient-Derived Cerebrospinal Fluid Circulating Tumor Cells for Experimental Therapeutics in Leptomeningeal Disease from Melanoma.

Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature

Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report

PA21 A child with longitudinal melanonychia secondary to subungual naevus showing regression during treatment with a single-agent MEK inhibitor (trametinib)

MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the Literature

Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib

Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model

Targeted therapy for pediatric low-grade glioma

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS -mutant lung cancer

New features in MEK retinopathy

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1

Combinatorial effects of azacitidine and trametinib on NRAS‐mutated melanoma

Case report: Treatment response of NF-1-associated bladder ganglioneuroma to trametinib

CNSC-12. NEURONAL DIFFERENTIATION DRIVES THE ANTI-TUMOR EFFICACY OF MEK INHIBITION IN GLIOBLASTOMA

A Case of Class 3 MEK1 Mutated Metastatic Colorectal Cancer with a Non-Durable Tumor Marker Response to MEK and ERK Inhibitors

Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors